Infinity Pharmaceuticals, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2001-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.infi.com
Clinical Trials
53
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (43 trials with phase data)• Click on a phase to view related trials
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
- Conditions
- Advanced CancerBladder CancerUrothelial CarcinomaSolid Tumor
- Interventions
- First Posted Date
- 2019-06-10
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 49
- Registration Number
- NCT03980041
- Locations
- 🇺🇸
Parkview Physicians, Fort Wayne, Indiana, United States
🇺🇸University of MD - Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Karmanos Cancer Center, Detroit, Michigan, United States
Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma
- Conditions
- Breast CancerRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 91
- Registration Number
- NCT03961698
- Locations
- 🇺🇸
Ironwood Cancer and Research Center, Chandler, Arizona, United States
🇺🇸Arizona Oncology Associates, Tucson, Arizona, United States
🇺🇸Arizona Clinical Research Center, Tucson, Arizona, United States
A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549
- Conditions
- Advanced Solid Tumors (Part A/B/C/D)Triple Negative Breast Cancer (Part F)Adrenocortical Carcinoma (Part G)Non-small Cell Lung Cancer (Part E)Mesothelioma (Part G)High-circulating Myeloid-derived Suppressor Cells (Part H)Melanoma (Part E)Squamous Cell Cancer of the Head and Neck (Part E)
- Interventions
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 219
- Registration Number
- NCT02637531
- Locations
- 🇺🇸
UCSD, San Diego, California, United States
🇺🇸UCLA, Santa Monica, California, United States
🇺🇸Hematology Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida, United States
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
- First Posted Date
- 2012-05-31
- Last Posted Date
- 2012-11-14
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01609179
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
🇺🇸Johns Hopkins, Baltimore, Maryland, United States
Phase 1b/2 Study of Retaspimycin HCl (IPI-504) in Combination With Everolimus in KRAS Mutant Non-small Cell Lung Cancer
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2014-11-13
- Lead Sponsor
- Infinity Pharmaceuticals, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT01427946
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next